Biotechnology company Imugene (ASX:IMU) said a bile tract cancer patient in its phase 1 metastatic advanced solid tumors trial for Vaxinia, a treatment candidate for bile tract cancer, remained in complete response, surpassing over two years in remission, according to a Tuesday filing with the Australian bourse.
Meanwhile, the trial's bile tract cancer expansion phase cleared its first group, with the three patients experiencing no dose-limiting toxicities, and is now open for enrollment of up to 10 patients, the filing said.
The company also secured a patent extension to 2040 from the US Patent and Trademark Office for patent application number 16/324,541, protecting its oncolytic virotherapy CF33, including Vaxinia and CHECKVacc, according to the filing.
Imugene shares fell past 2% in morning trade Wednesday.
Price (AUD): $0.05, Change: $-0.001, Percent Change: -2.13%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.